CAMX.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 geg. 2024 @ 13:59):

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally...

Stats
Dzisiejszy wolumen	181 236
Średni wolumen	110 816
Kapitalizacja rynkowa	30.83B
EPS	SEK0 ( 2024-05-07 )
Następna data zysków	( SEK0 ) 2024-07-16
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	71.43
ATR14	SEK1.260 (0.24%)

Wolumen Korelacja

Długi: 0.21 (neutral)

Krótki: -0.04 (neutral)

Signal:(58.889) Neutral

Camurus AB (publ) Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Camurus AB (publ) Korelacja - Waluta/Towar

0.33
( neutral )

-0.53
( weak negative )

-0.30
( neutral )

0.82
( strong )

0.09
( neutral )

-0.57
( weak negative )

Camurus AB (publ) Finanse

Annual	2023
Przychody:	SEK1.72B
Zysk brutto:	SEK1.58B (92.06 %)
EPS:	SEK7.78

FY	2023
Przychody:	SEK1.72B
Zysk brutto:	SEK1.58B (92.06 %)
EPS:	SEK7.78

FY	2022
Przychody:	SEK956.34M
Zysk brutto:	SEK853.08M (89.20 %)
EPS:	SEK1.010

FY	2021
Przychody:	SEK600.57M
Zysk brutto:	SEK515.22M (85.79 %)
EPS:	SEK-1.660

Financial Reports:

No articles found.

Camurus AB (publ)

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.